Background
We tried to identify subgroup of patients with Alzheimer's disease (AD) benefiting from cholinesterase inhibitors (ChEI) treatment using standardized low-resolution brain electromagnetic tomography (sLORETA) [1] , which allows to study cortical EEG sources in 6239 cortical grey matter voxels.
Materials and methods
Resting EEG was recorded in 20 mild to moderate AD patients (mean age= 75.04 years; 13 women and 7 men; MMSE 15-24) before and after 6 months and 2 years on ChEI (donepezil, rivastigmine, galantamine) treatment. Based on changes of MMSE scores after 2 years follow-up, 11 patients were classified as Non-responders (decrease of MMSE > 2) and 9 patients as Responders (decrease of MMSE < 2). The localization of the differences in activity between two groups (at baseline) and within groups (baseline vs. 6 months) was assessed by voxel-by-voxel ttests of the sLORETA images of the log-transformed computed current density power in seven frequency bands.
Results
At baseline, Non-responders had significantly greater current densities in delta and alpha frequency band, which sLORETA localized in frontal (BA 6, 8, 9, 32; alpha) and parieto-occipital (BA 7, 17, 39, 40; delta) areas. After 6 months of ChEI treatment only Responders showed an increase of beta current densities, mainly in left frontal and temporal cortex.
Conclusions
Our results suggest that there is a subgroup of AD patients (probably with more pronounced central cholinergic deficiency syndrome) with better response to ChEI treatment, which can be identified by means of new quantitative EEG technique (sLORETA).
